Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Barclays PLC

Barclays PLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 88.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 108,788 shares of the specialty pharmaceutical company’s stock after acquiring an additional 51,005 shares during the quarter. Barclays PLC owned approximately 0.20% of Supernus Pharmaceuticals worth $3,393,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 398 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Innealta Capital LLC bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Supernus Pharmaceuticals in the second quarter worth approximately $72,000.

Insiders Place Their Bets

In other news, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last three months. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Up 0.5 %

Shares of Supernus Pharmaceuticals stock opened at $35.59 on Tuesday. The firm has a fifty day simple moving average of $35.65 and a 200-day simple moving average of $32.28. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 33.26 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.29) earnings per share. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SUPN shares. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.